share_log

The One-year Earnings Decline Has Likely Contributed ToShandong Fengyuan Chemical's (SZSE:002805) Shareholders Losses of 50% Over That Period

The One-year Earnings Decline Has Likely Contributed ToShandong Fengyuan Chemical's (SZSE:002805) Shareholders Losses of 50% Over That Period

山東豐源化工的一年收益下降很可能是造成股東在此期間損失50%的原因。
Simply Wall St ·  06/07 20:40

Investors can approximate the average market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. Unfortunately the Shandong Fengyuan Chemical Co., Ltd. (SZSE:002805) share price slid 50% over twelve months. That's well below the market decline of 12%. Even if you look out three years, the returns are still disappointing, with the share price down31% in that time. Even worse, it's down 15% in about a month, which isn't fun at all.

投資者可以通過購買指數基金來近似平均市場回報。雖然單個股票可能會大獲成功,但很多股票無法獲得滿意的回報。不幸的是,山東豐元化工股份有限公司(SZSE:002805)的股價在12個月內下跌了50%。這遠低於市場下跌12%。即使您在三年內看看,收益仍然令人失望,股價在那段時間下降了31%。更糟糕的是,它在一個月左右下跌了15%,這一點都不有趣。

If the past week is anything to go by, investor sentiment for Shandong Fengyuan Chemical isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

如果過去一週無法證明投資者對山東豐元化工的情緒是積極的,那麼讓我們看看基本面和股票價格之間是否存在不匹配。

Shandong Fengyuan Chemical wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

在過去的12個月中,山東豐元化工並沒有盈利,因此其股票價格與每股收益(EPS)之間的強相關性不太可能。可以說,營業收入是我們下一個最好的選擇。一般來說,沒有利潤的公司預計每年都會以良好的速度增長營收。這是因爲如果營收增長微不足道並且不盈利,則難以確定公司是否可持續。

In just one year Shandong Fengyuan Chemical saw its revenue fall by 10%. That looks pretty grim, at a glance. The stock price has languished lately, falling 50% in a year. What would you expect when revenue is falling, and it doesn't make a profit? We think most holders must believe revenue growth will improve, or else costs will decline.

僅在一年內,山東豐元化工的營業收入就下降了10%。這看起來相當不樂觀。股價最近一直疲軟,一年內下跌了50%。如果營收下降並且不盈利,您會期望什麼?我們認爲大多數持有人必須相信營收增長將會改善,否則成本將會下降。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以看到以下收益和營收的變化情況(通過單擊圖像了解精確值)。

earnings-and-revenue-growth
SZSE:002805 Earnings and Revenue Growth June 8th 2024
SZSE:002805 收益和營收增長 2024年6月8日

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. It might be well worthwhile taking a look at our free report on Shandong Fengyuan Chemical's earnings, revenue and cash flow.

我們很高興地報告,該公司首席執行官的薪酬比同樣資本化的公司的大多數首席執行官更爲適度。始終值得注意的是CEO的薪酬,但更重要的問題是公司是否會在未來幾年內增加收益。這可能值得一看,我們有報告介紹山東豐元化工的收益,營收和現金流。

A Different Perspective

不同的觀點

While the broader market lost about 12% in the twelve months, Shandong Fengyuan Chemical shareholders did even worse, losing 50%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 2% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 3 warning signs for Shandong Fengyuan Chemical that you should be aware of before investing here.

雖然更廣泛的市場在12個月內下跌了約12%,但豐元股份的股東表現更差,虧損了50%。然而,這可能僅僅是股價受到更廣泛市場動盪的影響。有必要關注基本面,以防有好的機會。 此外,長期股東賺了錢,過去五年每年增長2%。如果基本數據繼續表明長期可持續增長,目前的拋售可能是值得考慮的機會。 考慮到市場條件可能對股價產生的不同影響,但有些更重要的因素應注意。例如,我們已發現3個警告信號,您應在在此處投資之前了解。

We will like Shandong Fengyuan Chemical better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.

如果我們看到一些大量內部買入,我們將更喜歡山東豐元化工。等待時,請查看此免費的股票低估清單(主要是小市值股票),其中有相當多的最近的內部買入。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論